Roivant Subsidiaries Secure $2.25 Billion Settlement with Moderna Over COVID-19 Vaccine Patents
Event summary
- Roivant's Genevant Sciences and Arbutus Biopharma reached a $2.25 billion settlement with Moderna over patent infringement related to COVID-19 vaccines.
- Moderna will pay $950 million upfront in July 2026, with an additional $1.3 billion contingent on a favorable appellate ruling.
- The settlement includes a global non-exclusive license for Moderna to use Genevant's LNP delivery technology for infectious disease applications.
- Roivant's board approved a $1 billion share repurchase program, including a $500 million authorization from June 2025.
The big picture
This settlement underscores the high-stakes nature of intellectual property disputes in the biopharmaceutical industry, particularly around foundational technologies like LNP delivery systems. The resolution provides Roivant with significant financial flexibility, while the ongoing litigation against Pfizer/BioNTech highlights the broader industry dynamics around patent protection and vaccine development. The deal size and strategic implications mark a pivotal moment in the validation of Genevant's and Arbutus's patent portfolio.
What we're watching
- Litigation Impact
- How the ongoing litigation against Pfizer/BioNTech will affect Roivant's strategic positioning and financial outcomes.
- Capital Efficiency
- Whether Roivant can sustain capital efficiency with the proceeds from the settlement and share repurchase program.
- Technology Licensing
- The pace at which Genevant's LNP delivery technology will be licensed to other biopharmaceutical companies.
Related topics